Dentsply Sirona Stock Sinks On Missed Expectations, Lowered 2025 Guidance; CEO Unveils Return-To-Growth Plan

Dentsply Sirona (XRAY) shares fell over 12% after the company reported third-quarter adjusted earnings of 37 cents per share, missing the 45-cent consensus, despite sales of $904 million slightly exceeding estimates. The earnings decline was attributed to sales mix, tariffs, and higher taxes, prompting the company to lower its fiscal 2025 adjusted EPS guidance to $1.60 from a previous range of $1.80-$2.00. CEO Dan Scavilla acknowledged operational and strategic challenges, announcing a new "Return-to-Growth" strategy and the departure of the CFO.

Analysis

Dentsply Sirona (XRAY) shares experienced a significant 12.14% decline following its third-quarter earnings report, which presented a mixed financial picture. Adjusted earnings per share of $0.37 missed the consensus estimate of $0.45, despite sales of $904 million exceeding the $896.71 million forecast. The earnings shortfall was primarily attributed to an unfavorable sales mix, tariffs, and a higher tax rate, although adjusted EBITDA margin improved by 50 basis points to 18.4% due0 to reduced operating expenses.

The company also revised its fiscal 2025 adjusted EPS guidance downwards to $1.60, from a previous range of $1.80-$2.00, falling below the $1.88 consensus. CEO Dan Scavilla acknowledged "operational and strategic challenges" and announced a "Return-to-Growth" strategy, targeting sustained profitable growth within the next 24 months. This strategic pivot aims to address underlying issues impacting key segments like Orthodontic and Implant Solutions, which saw a 15% sales decline.

Further compounding uncertainty, CFO Matt Garth has departed, with Leslie Varon appointed as interim finance chief. While the company retained its Wellspect subsidiary, citing its position in a $2 billion addressable market, the immediate focus remains on executing the new growth strategy amidst leadership transition and persistent headwinds from lower volumes in Connected Technology Solutions and specific market weakness in the U.S. and China.

Key Decisions for Investors

• Closely monitor the execution and initial results of the "Return-to-Growth" strategy, especially progress towards the 24-month target for sustained profitable growth.
• Assess the implications of the CFO transition, including the appointment of an interim finance chief, on financial reporting stability and strategic continuity.
• Evaluate segment-specific performance, particularly in Orthodontic and Implant Solutions and Connected Technology, for signs of stabilization or further volume recovery in key markets.